A missense mutation in human fatty acid amide hydrolase associated with problem drug use

Jack C. Sipe, Kyle P. Chiang, Alexandra Lehmkuhl Gerber, Ernest Beutler, Benjamin F. Cravatt

Proceedings of the National Academy of Sciences · 2002 · 358 citations · 23 references

DOIFull text

Open access

Concepts

TL;DR

Problem drug use and dependence are neurobehavioral disorders of complex origin, with genetic factors contributing 40–60 % of risk, yet the specific genes involved remain largely unknown. The study reports a naturally occurring FAAH missense mutation (Pro129→Thr) that, in homozygous form, is strongly linked to street drug use and problem drug/alcohol use. The mutation converts a conserved proline to threonine, producing a FAAH variant with normal catalytic activity but heightened proteolytic degradation. These findings indicate that FAAH mutations are significant risk factors for drug abuse, linking endogenous cannabinoid system dysfunction to dependence.

Abstract

Problem drug use and dependence are neurobehavioral disorders of complex origin. Although environmental factors contribute to drug abuse and addiction, genetic factors also play a significant role estimated at 40–60% of the total risk. Nonetheless, the precise identities of human genes that confer vulnerability to problem drug use remain mostly unknown. Here, we describe a natural single nucleotide polymorphism in the human gene that encodes the principal endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), that in homozygous form is strongly associated with both street drug use and problem drug/alcohol use. This single nucleotide polymorphism results in a missense mutation (385C→A) that converts a conserved proline residue to threonine (Pro129→Thr), producing a FAAH variant that displays normal catalytic properties but an enhanced sensitivity to proteolytic degradation. Collectively, these results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence.

References

23